Supplemental Disclosure of Cash Flow Information |
Supplemental Disclosure of Cash Flow Information | | | | | | | | | | Three Months Ended March 31, | (in thousands) | 2020 | | 2019 | Supplemental Disclosure of Cash Flow Information: | | | | Interest paid | $ | 59,479 |
| | $ | 62,107 |
| Income taxes paid, net of refunds | 957 |
| | 606 |
| | | | | Capital expenditures, net of related payables | | | | Capital expenditures - non-development, net | $ | 60,556 |
| | $ | 54,602 |
| Capital expenditures - development, net | 3,900 |
| | 5,269 |
| Capital expenditures - non-development - reimbursable | 5,827 |
| | — |
| Trade accounts payable | (898 | ) | | 184 |
| Net cash paid | $ | 69,385 |
| | $ | 60,055 |
| Acquisition of communities from Healthpeak | | | | Property, plant and equipment and leasehold intangibles, net | $ | 286,734 |
| | $ | — |
| Operating lease right-of-use assets | (63,285 | ) | | — |
| Financing lease obligations | 129,196 |
| | — |
| Operating lease obligations | 74,335 |
| | — |
| Loss (gain) on debt modification and extinguishment, net | (19,731 | ) | | — |
| Net cash paid | $ | 407,249 |
| | $ | — |
| Acquisition of other assets, net of related payables and cash received: | | | | Property, plant and equipment and leasehold intangibles, net | $ | 179 |
| | $ | 32,126 |
| Financing lease right-of-use assets | 39,260 |
| | — |
| Other intangibles assets, net | — |
| | (4,796 | ) | Net cash paid | $ | 39,439 |
| | $ | 27,330 |
| Proceeds from Sale of CCRC Venture, net | | | | Investment in unconsolidated ventures | $ | (14,848 | ) | | $ | — |
| Current portion of long-term debt | 34,706 |
| | — |
| Accrued expenses | (5,025 | ) | | — |
| Other liabilities | 60,748 |
| | — |
| Loss (gain) on sale of assets, net | (370,745 | ) | | — |
| Net cash received | $ | (295,164 | ) | | $ | — |
| Proceeds from sale of other assets, net | | | | Prepaid expenses and other assets, net | $ | (1,261 | ) | | $ | (231 | ) | Assets held for sale | (5,274 | ) | | (29,550 | ) |
| | | | | | | | | Property, plant and equipment and leasehold intangibles, net | — |
| | (457 | ) | Other liabilities | (824 | ) | | 78 |
| Loss (gain) on sale of assets, net | (2,094 | ) | | 702 |
| Net cash received | $ | (9,453 | ) | | $ | (29,458 | ) | | | | | Supplemental Schedule of Non-cash Operating, Investing and Financing | | | | Purchase of treasury stock: | | | | Treasury stock | $ | — |
| | $ | 288 |
| Accounts payable | — |
| | (288 | ) | Net | $ | — |
| | $ | — |
| Assets designated as held for sale: | | | | Assets held for sale | $ | — |
| | $ | (5,249 | ) | Property, plant and equipment and leasehold intangibles, net | — |
| | 5,249 |
| Net | $ | — |
| | $ | — |
| Healthpeak master lease modification | | | | Property, plant and equipment and leasehold intangibles, net | $ | (57,462 | ) | | $ | — |
| Operating lease right-of-use assets | 88,044 |
| | — |
| Financing lease obligations | 70,874 |
| | — |
| Operating lease obligations | (101,456 | ) | | — |
| Net | $ | — |
| | $ | — |
| Other lease termination and modification, net: | | | | Prepaid expenses and other assets, net | $ | — |
| | $ | (160 | ) | Property, plant and equipment and leasehold intangibles, net | (9,441 | ) | | 175 |
| Financing lease obligations | 9,516 |
| | — |
| Other liabilities | (75 | ) | | (224 | ) | Loss (gain) on facility lease termination and modification, net | — |
| | 209 |
| Net | $ | — |
| | $ | — |
|
Restricted cash consists principally of escrow deposits for real estate taxes, property insurance, and capital expenditures required by certain lenders under mortgage debt agreements and deposits as security for self-insured retention risk under workers' compensation programs and property insurance programs. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sums to the total of the same such amounts shown in the condensed consolidated statements of cash flows. | | | | | | | | | (in thousands) | March 31, 2020 | | December 31, 2019 | Reconciliation of cash, cash equivalents, and restricted cash: | | | | Cash and cash equivalents | $ | 392,674 |
| | $ | 240,227 |
| Restricted cash | 23,908 |
| | 26,856 |
| Long-term restricted cash | 41,917 |
| | 34,614 |
| Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows | $ | 458,499 |
| | $ | 301,697 |
|
|